Literature DB >> 9134072

A protocol to switch high-dose, methadone-maintained subjects to buprenorphine.

F R Levin1, M W Fischman, I Connerney, R W Foltin.   

Abstract

Buprenorphine (BUP) is an alternative to methadone (METH) maintenance. However, there are few studies on the switching of patients from METH to BUP. Eighteen volunteers who had been maintained on METH for 1-19 years were recruited for a residential cocaine self-administration study. All subjects were maintained on 60 mg METH for up to 1 1/2 weeks before the 7-day changeover (60, 40, 30, 30, 0 mg METH; 4, 8 mg BUP). Fifteen subjects successfully completed the transfer from METH to BUP, experiencing moderate withdrawal symptoms, as measured by the Subjective Opiate Withdrawal Scale (SOWS). Withdrawal symptoms were the highest during the first assessment of the day, at the time of BUP administration. SOWS scores returned to baseline 4 days after the switchover. This study demonstrates that within a supportive inpatient setting, research volunteers can be rapidly switched from high-maintenance doses of METH to BUP with an acceptable degree of tolerability.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9134072     DOI: 10.3109/10550499709137021

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  9 in total

Review 1.  Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.

Authors:  Paolo Mannelli; Kathleen S Peindl; Tong Lee; Kamal S Bhatia; Li-Tzy Wu
Journal:  Curr Drug Abuse Rev       Date:  2012-03

Review 2.  Pharmacological strategies for detoxification.

Authors:  Alison M Diaper; Fergus D Law; Jan K Melichar
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

3.  Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.

Authors:  Babak Tofighi; Arthur Robin Williams; Chemi Chemi; Selena Suhail-Sindhu; Vicky Dickson; Joshua D Lee
Journal:  Subst Use Misuse       Date:  2019-08-20       Impact factor: 2.164

Review 4.  Development of vaccines to treat opioid use disorders and reduce incidence of overdose.

Authors:  Marco Pravetoni; Sandra D Comer
Journal:  Neuropharmacology       Date:  2019-06-04       Impact factor: 5.250

Review 5.  Opioid dependence treatment: options in pharmacotherapy.

Authors:  Angela L Stotts; Carrie L Dodrill; Thomas R Kosten
Journal:  Expert Opin Pharmacother       Date:  2009-08       Impact factor: 3.889

6.  Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: the Bernese method.

Authors:  Robert Hämmig; Antje Kemter; Johannes Strasser; Ulrich von Bardeleben; Barbara Gugger; Marc Walter; Kenneth M Dürsteler; Marc Vogel
Journal:  Subst Abuse Rehabil       Date:  2016-07-20

Review 7.  Practical considerations for the clinical use of buprenorphine.

Authors:  Hendree E Jones
Journal:  Sci Pract Perspect       Date:  2004-08

8.  Metabolic and Addiction Indices in Patients on Opioid Agonist Medication-Assisted Treatment: A Comparison of Buprenorphine and Methadone.

Authors:  Igor Elman; Margaret Howard; Jacob T Borodovsky; David Mysels; David Rott; David Borsook; Mark Albanese
Journal:  Sci Rep       Date:  2020-03-27       Impact factor: 4.379

9.  Strategies for Transfer From Methadone to Buprenorphine for Treatment of Opioid Use Disorders and Associated Outcomes: A Systematic Review.

Authors:  Nicholas Lintzeris; Baher Mankabady; Carlos Rojas-Fernandez; Halle Amick
Journal:  J Addict Med       Date:  2022 Mar-Apr 01       Impact factor: 3.702

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.